| dc.contributor.advisor | Weber, Martin Prof. Dr. | |
| dc.contributor.author | Hajiyeva, Zivar | |
| dc.date.accessioned | 2021-11-29T14:08:49Z | |
| dc.date.available | 2021-12-16T00:50:03Z | |
| dc.date.issued | 2021-11-29 | |
| dc.identifier.uri | http://hdl.handle.net/21.11130/00-1735-0000-0008-59AE-1 | |
| dc.identifier.uri | http://dx.doi.org/10.53846/goediss-8966 | |
| dc.language.iso | eng | de |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.subject.ddc | 610 | de |
| dc.title | The effect of glatiramer acetate on functional properties of B lymphocytes in patients with MS | de |
| dc.type | doctoralThesis | de |
| dc.contributor.referee | Huppke, Peter Prof. Dr. | |
| dc.date.examination | 2021-12-08 | |
| dc.description.abstracteng | Objective: We examined the effect of glatiramer acetate (GA) on B-cell maturation, differentiation, and antigen presentation in MS patients.
Methods: A cross-sectional study of blood samples from 20 GA-treated and 18 untreated patients with MS was performed by flow cytometry; 6 GA-treated patients with MS were analyzed longitudinally.
Results: In MS, GA diminished transitional B-cell and plasmablast frequency, downregulated CD69, CD25, and CD95 expression, and decreased TNF-α production, whereas IL-10 secretion and MHC Class II expression were increased.
Conclusions: GA immune modulates B-cell function in MS. | de |
| dc.contributor.coReferee | Flügel, Alexander Prof. Dr. | |
| dc.subject.eng | B cells | de |
| dc.subject.eng | Multiple sclerosis | de |
| dc.subject.eng | glatiramer acetate | de |
| dc.identifier.urn | urn:nbn:de:gbv:7-21.11130/00-1735-0000-0008-59AE-1-4 | |
| dc.affiliation.institute | Medizinische Fakultät | de |
| dc.subject.gokfull | Neurologie - Allgemein- und Gesamtdarstellungen (PPN619876247) | de |
| dc.description.embargoed | 2021-12-16 | |
| dc.identifier.ppn | 1779806256 | |